|Bid||10,410.00 x 0|
|Ask||10,800.00 x 0|
|Day's Range||10,540.00 - 10,626.00|
|52 Week Range||8,250.00 - 11,886.00|
|Beta (5Y Monthly)||0.16|
|PE Ratio (TTM)||48.56|
|Earnings Date||Nov 10, 2022|
|Forward Dividend & Yield||2.22 (2.21%)|
|Ex-Dividend Date||Aug 11, 2022|
|1y Target Est||117.23|
Higher sales of AstraZeneca's (AZN) key medicines, Lynparza, Tagrisso and Imfinzi and Farxiga are expected to have driven sales, partially offset by lower sales of legacy drugs.
AstraZeneca PLC said Tuesday that Forxiga has been approved in the European Union for the treatment of symptomatic chronic heart failure.
The following are the top stories on the business pages of British newspapers. The Times - The UK is losing out on investment from AstraZeneca Plc to more competitive countries, Tom Keith-Roach, the head of the company, warned. - A British semiconductor company, IQE Plc could move overseas unless the government sets out its strategy for the sector in the next six months, its chief executive said.